Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week comparison of BF Spiromax versus Symbicort Turbohaler in persistent asthma
2013-000081-11Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Apr 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of budesonide + formoterol in persistent asthma (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Change from baseline in weekly average of daily trough morning peak expiratory flow over 12 weeks. Started Apr 2013; status: completed.
02
Drugs
budesonide + formoterol
03
Conditions
persistent asthma
Beyond the preview
Go deeper on 2013-000081-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000081-11.